Figure 12

Morphological assessment of apoptotic development of MCF 7 cells by double staining technique using inverted phase contrast microscope. (A) Normal viable cells under ×20 magnification. (B) Normal viable cells under ×40 magnification. (C) Cisplatin treated at the concentration of 4 µg/mL under ×20 magnification. (D) Cisplatin treated at the concentration of 4 µg/mL under ×40 magnification, the arrow mark showing both viable cells and early development of apoptosis. (E) Cisplatin treated at the concentration of 8 µg/mL under ×20 magnification. (F) Cisplatin treated at the concentration of 8 µg/mL under ×40 magnification, the arrow mark showing both viable cells and late development of apoptosis, chromatin condensation and secondary necrosis development. (G) CCNP treated at the concentration of 3.5 µg/mL under 20 × magnification. (H) CCNP treated at the concentration of 3.5 µg/mL under 40 × magnification, the arrow mark showing the chromatin condensation. (I) CCNP treated at the concentration of 7 µg/mL under ×40 magnification. (J) CCNP treated at the concentration of 7 µg/mL under ×40 magnification, the arrow mark showing the late apoptosis, chromatin condensation and blebbing of the cell membrane. VI: Viable cells; EA: Early Apoptosis; LA: Late Apoptosis; CC: Chromatin condensation; SN: Secondary necrosis; BL: Blebbing of the cell membrane.